Welcome to our dedicated page for Nymox Pharm news (Ticker: NYMXF), a resource for investors and traders seeking the latest updates and insights on Nymox Pharm stock.
Nymox Pharmaceutical Corporation (NYMXF) is a pharmaceutical preparation manufacturing company whose news flow centers on the development, regulatory review, and legal context surrounding its drug candidate NYMOZARFEX™ (Fexapotide). Company updates frequently describe progress and challenges in seeking approval to market NYMOZARFEX for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer.
News items from Nymox often highlight clinical data and long-term follow-up results. The company has reported 10-year follow-up data from its U.S. clinical trial of NYMOZARFEX for low grade localized prostate cancer, stating that the treatment produced important and statistically significant reductions in long-term cancer progression. Releases also describe the safety profile of NYMOZARFEX, with Nymox emphasizing the absence of side effects typically associated with existing BPH treatments.
Regulatory developments are another key theme in NYMXF news. Nymox has issued detailed updates on its marketing authorization applications to agencies such as the Danish Medicines Agency and the UK’s MHRA, including feedback, outstanding questions, and the need for re-submission where timelines expired. These communications provide insight into the regulatory review process for NYMOZARFEX and the company’s responses.
In addition, Nymox’s news coverage includes legal and corporate matters, such as litigation involving former executives, actions in courts in the United States and the Bahamas, and disputes with third parties. The company also reports on trading status and market tier changes for its stock, including its listing on the OTCQB Venture Market under the symbol NYMXF. Investors following NYMXF news can review these updates to understand the evolving clinical, regulatory, legal, and trading context for Nymox.
Nymox Pharmaceutical (OTCQB:NYMXF) announced Board changes and corporate updates on March 27, 2026. Patrick Doody has retired from the Board and the company confirmed the recent passing of Co-Chairman James G. Robinson. The company said prostate treatment dossiers were significantly updated but no major approvals yet.
CEO Paul Averback MD purchased 50,000 shares in the open market, adding to a prior October 2025 purchase of 102,844 shares.
Nymox has announced the dismissal of its Delaware legal action against Ascella on March 7, 2025. The company stated this decision came after reconsidering its strategy to protect shareholders' interests. CEO Paul Averback indicated this dismissal is a legal step taken after consultation with legal counsel, and mentioned that additional steps are being contemplated, which will be reported at an appropriate time.
Nymox Pharmaceutical (NYMXF) has announced the resumption of its stock trading on the OTCQB Venture Market, representing an upgrade from its previous listing tier. This new listing makes the stock eligible for proprietary broker-dealer quotations. The company's president, Paul Averback, expressed gratitude towards the OTC teams for their guidance during the transition process and thanked shareholders and investors for their patience and support. He emphasized the company's focus on advancing prostate treatments to address the market's need for safer and more effective solutions.
Nymox Pharmaceutical (OTC: NYMXF) has announced the filing of its Annual Report with the Securities and Exchange Commission (SEC) on August 29, 2024. The company, which trades on the OTC Markets, made this announcement on August 30, 2024, from Irvine, California. This timely filing of the Annual Report is a important regulatory compliance step for publicly traded companies, providing investors and regulators with essential financial and operational information about the company's performance over the past year.
Nymox Pharmaceutical (OTC: NYMXF) has announced an update on its Annual Report progress. The company began working on the report in late February after receiving previously withheld corporate documents from terminated officers and directors. This situation has led to unexpected delays in completing the report. Despite these challenges, Nymox expects the audit to be finalized soon, with the Annual Report to be issued shortly after. The company acknowledges the delay is beyond its control and is working to release the report as quickly as possible.
Nymox Pharmaceutical (OTC: NYMXF) announced that its Marketing Authorization Application (MAA) to the Danish Medicines Agency (DKMA) for Nymozarfex™ has expired and requires resubmission with a new fee. The current application does not meet the Medicines Act conditions for marketing authorization. Key issues include:
1. Developing an assay method for impurities below 0.1%
2. Providing additional evidence of double-blinding in long-term follow-up studies
3. Addressing remaining questions about data analysis
Nymox believes it has the necessary data for resubmission but cannot guarantee resolution of all issues. The company's MAA to the UK's MHRA is still in process. No significant safety concerns were reported for Nymozarfex in human clinical trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.